Adimab, LLC, the technology leader in the discovery of monoclonal and bispecific antibodies, today announced independent discovery collaborations with Acceleron Pharma, Inc., Oncothyreon, Inc., Surface Oncology, Inc. and Potenza Therapeutics, Inc. All four collaborations are structured as funded discovery programs in which Adimab will discover and optimize therapeutic monoclonal or bispecific antibodies against multiple targets for each partner.  Read More